Eliaz Therapeutics Inc. filed a Form D with the Securities and Exchange Commission on 2025-10-24.
Eliaz Therapeutics Inc. filed a Form D notice of an exempt securities offering with the SEC on October 24, 2025. The filing reports $850K sold. Its industry group is Biotechnology. It names Isaac Eliaz (Executive Officer, Director), Milton Goss (Executive Officer) (SEC Form D, October 24, 2025).
Is this your company?
Sell to companies like Eliaz Therapeutics Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
New Form D on file · 2025-10-24 · the record
Pitching, partnering or investing alongside them? See who really runs and owns Eliaz Therapeutics Inc.
Free to see. No signup.
More on the people and the money behind Eliaz Therapeutics Inc., from the filings we hold.
Biotechnology raises by companies based in California, filed in October 2025, largest first.
Get an email when Eliaz Therapeutics Inc. files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
We'll show it in your MentionFox inbox when Eliaz Therapeutics Inc. raises, hires or launches. No email unless you switch it on.
Watch Eliaz Therapeutics Inc. →Get the full cited report on Eliaz Therapeutics Inc.
What the filing shows about Eliaz Therapeutics Inc.
Only in the Full Report: Who Runs It, And How To Reach Them · Warning Bells · Who Pays Them, And Who They Are Up Against.
Example from a real report (our sample on Target): “In March 2026, Target announced a planned incremental $1 billion operating investment” Source: Target Corporation (press release)
A Full Report on Eliaz Therapeutics Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
The filing gives Eliaz Therapeutics Inc.'s address as 398 Tesconi Court, Santa Rosa, CA 95401.
Saved here on this device in the meantime, so nothing is lost either way.
This is the company's own disclosure. A payment disclosed on a Form D is a disclosed use of proceeds, not a finding of wrongdoing.
Order the Full Report on Eliaz Therapeutics Inc. See pricing
Eliaz Therapeutics Inc. is a registered filer with the SEC (CIK 2042609) and has filed since 2025-10-24. 1 filing is on record, the latest on 2025-10-24.
A filing shows the company exists and what it reports about itself. It is not an audit or a rating.
Eliaz Therapeutics Inc.'s Form D of 2025-10-24 names Isaac Eliaz and Milton Goss as its officers, directors or promoters.
Its new offerings report $850K sold across 1 offering, as its own filings state.
Trailing twelve months. 766 filings in Biotechnology, totalled by week.
A portion of the proceeds may be used to pay executive salaries but would not be deemed compensation for sales under this offering.
Checked away from the filing. What is below does not come from the record on sec.gov.
MedTech company dedicated to advancing innovative treatments for life-threatening inflammatory conditions. Every 2.8 seconds, someone dies from sepsis.
The title and description the site itself served, answering 200. Not a cached copy and not the company's directory entry — what was live when we asked.
Isaac Eliaz is named as Executive Officer and Director on the Form D that Eliaz Therapeutics Inc. filed with the SEC on 24 October 2025, one of 2 people that filing names.
Milton Goss is named as Executive Officer on the Form D that Eliaz Therapeutics Inc. filed with the SEC on 24 October 2025, one of 2 people that filing names.
2 people named on the filing — 2 holding an executive role.
Named as of the 2025-10-24 filing. Titles and locations are exactly as the filing states — not independently confirmed elsewhere.
What the filing shows about Eliaz Therapeutics Inc.
Only in the Full Report: Who Runs It, And How To Reach Them · Warning Bells · Who Pays Them, And Who They Are Up Against.
Example from a real report (our sample on Target): “In March 2026, Target announced a planned incremental $1 billion operating investment” Source: Target Corporation (press release)
A Full Report on Eliaz Therapeutics Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Eliaz Therapeutics Inc. covers
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
You land back on this company when you are in.
Not ready to upgrade? Keep this one in view instead.
Watchlist Eliaz Therapeutics Inc.You get an alert in MentionFox the next time this company shows up.
If you're behind Eliaz Therapeutics Inc.: the weeks after a raise are watched the same way — by other investors sizing you up, and by founders checking who just got funded. FoxPlug turns your commits, deploys, and releases into that story automatically. GetFoxChat puts a guide on your own site so the people this filing just sent you don't leave after one page.
Sourced from the filing index on sec.gov, and from the company's own site, read directly on 2026-10-30 (eliaztherapeutics.com).
Each opens in a new tab, filled in for Eliaz Therapeutics Inc.. With no account yet, you sign up free and land on the result.
Share your raise. This card is drawn from the company's own Form D filing, and sharing needs no account.
https://mentionfox.com/funding/eliaz-therapeutics-inc-form-d-25000001